HOB Biotech Group Corp Ltd (688656) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HOB Biotech Group Corp Ltd (688656) has a cash flow conversion efficiency ratio of 0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥34.39 Million ≈ $5.03 Million USD) by net assets (CN¥829.05 Million ≈ $121.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
HOB Biotech Group Corp Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how HOB Biotech Group Corp Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does HOB Biotech Group Corp Ltd carry for a breakdown of total debt and financial obligations.
HOB Biotech Group Corp Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HOB Biotech Group Corp Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CATARC Automotive Proving Ground Co.Ltd.
SHE:301215
|
N/A |
|
Mahanagar Gas Limited
NSE:MGL
|
0.003x |
|
Rolls-Royce Holdings PLC
LSE:RR
|
0.829x |
|
Betsson AB
ST:BETS-B
|
0.074x |
|
Grupo Herdez S.A.B. de C.V
MX:HERDEZ
|
0.020x |
|
Ramkrishna Forgings Limited
NSE:RKFORGE
|
-0.002x |
|
Zhongnongfa Seed Industry Group Co Ltd
SHG:600313
|
-0.022x |
|
Yeni Gimat Gayrimenkul Yatirim Ortakligi AS
IS:YGGYO
|
0.087x |
Annual Cash Flow Conversion Efficiency for HOB Biotech Group Corp Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of HOB Biotech Group Corp Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see HOB Biotech Group Corp Ltd (688656) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥812.14 Million ≈ $118.84 Million |
CN¥101.22 Million ≈ $14.81 Million |
0.125x | -1.61% |
| 2023-12-31 | CN¥810.73 Million ≈ $118.64 Million |
CN¥102.69 Million ≈ $15.03 Million |
0.127x | +69.36% |
| 2022-12-31 | CN¥779.57 Million ≈ $114.08 Million |
CN¥58.31 Million ≈ $8.53 Million |
0.075x | -45.04% |
| 2021-12-31 | CN¥770.00 Million ≈ $112.68 Million |
CN¥104.79 Million ≈ $15.33 Million |
0.136x | -51.76% |
| 2020-12-31 | CN¥206.39 Million ≈ $30.20 Million |
CN¥58.22 Million ≈ $8.52 Million |
0.282x | -38.44% |
| 2019-12-31 | CN¥149.64 Million ≈ $21.90 Million |
CN¥68.57 Million ≈ $10.03 Million |
0.458x | +31.16% |
| 2018-12-31 | CN¥133.12 Million ≈ $19.48 Million |
CN¥46.51 Million ≈ $6.81 Million |
0.349x | +24.05% |
| 2017-12-31 | CN¥79.03 Million ≈ $11.56 Million |
CN¥22.26 Million ≈ $3.26 Million |
0.282x | +148.76% |
| 2016-12-31 | CN¥56.71 Million ≈ $8.30 Million |
CN¥6.42 Million ≈ $939.60K |
0.113x | -- |
About HOB Biotech Group Corp Ltd
HOB Biotech Group Corp.,Ltd. operates as a in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immuno assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. The company was founded in 2009 and is based in Suzhou, Ch… Read more